Departments of General Surgery.
Department of General Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.
Appl Immunohistochem Mol Morphol. 2023 Feb 1;31(2):84-93. doi: 10.1097/PAI.0000000000001089. Epub 2022 Nov 22.
Heterogeneous mismatch repair (MMR) status in metastatic colorectal cancer (mCRC) may associate with refractoriness to immunotherapy. We aimed here to study the concordance in MMR status between primary and paired metastasis in mCRC. Our study included 84 patients diagnosed with mCRC with primary and matched metastatic cancers. Immunohistochemistry was used to determine the MMR status of primary lesions and matched metastases. Pooled analysis of 913 cases was used to evaluate the prevalence and organ specificity of MMR status heterogeneity. The correlations between MMR pattern heterogeneity and clinical outcomes were analyzed. MMR status heterogeneity between primary and corresponding metastatic sites was exhibited by 10 (11.9%) patients. The prevalence of the heterogeneous MMR phenotype was significantly higher in primary tumors with deficient MMR (dMMR) than with proficient MMR (pMMR), which was verified in the pooled analysis ( P <0.001). Among patients with a dMMR primary tumor, the discrepancy was detected in liver, lung, ovary, peritoneum, and distant lymph node metastases. However, the discrepancy was confined to liver (26/440) or peritoneum (7/112) ( P =0.02) in patients with a pMMR primary tumor. Patients with or without MMR status heterogeneity experienced comparable overall survival ( P =0.452). Heterogeneous MMR patterns generally existed in a subset of patients with mCRC, particularly those with dMMR primary tumors. Testing the metastatic site may be valuable because the discordance of MMR status may potentially affect immune surveillance and immunotherapy.
转移性结直肠癌(mCRC)中异质性错配修复(MMR)状态可能与免疫治疗的耐药性有关。我们旨在研究 mCRC 原发灶和配对转移灶中 MMR 状态的一致性。本研究纳入了 84 例 mCRC 患者,其具有原发灶和匹配的转移性癌症。免疫组织化学用于确定原发灶和匹配转移灶的 MMR 状态。对 913 例病例的汇总分析用于评估 MMR 状态异质性的发生率和器官特异性。分析了 MMR 模式异质性与临床结局之间的相关性。10 例(11.9%)患者的原发灶和相应转移灶之间表现出 MMR 状态异质性。在 MMR 缺陷(dMMR)的原发肿瘤中,异质性 MMR 表型的发生率明显高于 MMR 功能良好(pMMR)的原发肿瘤,这在汇总分析中得到了验证(P<0.001)。在 dMMR 原发肿瘤患者中,在肝、肺、卵巢、腹膜和远处淋巴结转移中检测到差异。然而,在 pMMR 原发肿瘤患者中,差异仅限于肝(26/440)或腹膜(7/112)(P=0.02)。有无 MMR 状态异质性的患者的总生存情况相当(P=0.452)。异质性 MMR 模式通常存在于 mCRC 的一部分患者中,特别是那些具有 dMMR 原发肿瘤的患者。检测转移灶可能是有价值的,因为 MMR 状态的不一致可能会潜在地影响免疫监测和免疫治疗。